Page last updated: 2024-11-07

fructose 2,6-diphosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

fructose 2,6-diphosphate: phosphofructokinase activator synthesized via Mg-ATP & fructose-6-P [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

beta-D-fructofuranose 2,6-bisphosphate : A D-fructofuranose 2,6-bisphosphate with a beta-configuration at the anomeric centre. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID105021
CHEBI ID28602
SCHEMBL ID504427
MeSH IDM0089703

Synonyms (29)

Synonym
CHEBI:28602
79082-92-1
2,6-di-o-phosphono-beta-d-fructofuranose
beta-d-fructofuranose 2,6-bisphosphate
beta-d-fructofuranose 2,6-bis(dihydrogen phosphate)
beta-d-fructose 2,6-bisphosphate
d-fructose 2,6-bisphosphate
C00665
fructose 2,6-diphosphate
fructose-2,6-diphosphate
phosphofructokinase activator
fructose 2,6-bisphosphate
fructose 2,6-biphosphate
phosphofructokinase activation factor
BMSE000275
beta-d-fructofuranose, 2,6-bis(dihydrogen phosphate)
[(2s,3s,4s,5r)-3,4-dihydroxy-2-(hydroxymethyl)-5-(phosphonooxymethyl)oxolan-2-yl] dihydrogen phosphate
unii-se96vbe4lu
se96vbe4lu ,
SCHEMBL504427
CS-7888
{[(2r,3s,4s,5s)-3,4-dihydroxy-5-(hydroxymethyl)-5-(phosphonooxy)oxolan-2-yl]methoxy}phosphonic acid
fru 2,6-p2, fructose 2,6-diphosphate
b-d-fructose 2,6-bisphosphate
HY-12314
DTXSID90897603
(2s,3s,4s,5r)-3,4-dihydroxy-2-(hydroxymethyl)-5-((phosphonooxy)methyl)tetrahydrofuran-2-yl dihydrogen phosphate
b-d-fructofuranose,2,6-bis(dihydrogenphosphate)
beta-d-fructose 2,6-diphosphate

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"8 mmol/L (50 mg/dL) without insulin infusion revealed that the half-life of plasma endogenous insulin was 173 min, indicating severely impaired plasma insulin clearance."( Hyperinsulinemia due to impaired insulin clearance associated with fasting hypoglycemia and postprandial hyperglycemia: an analysis of a patient with antiinsulin receptor antibodies.
Hamaguchi, T; Kawachi, M; Kiyokawa, H; Kono, N; Kuwajima, M; Mineo, I; Shimizu, T; Tajima, K; Tarui, S; Yamada, Y, 1989
)
0.28

Dosage Studied

ExcerptRelevanceReference
" This could be suppressed by increasing the gene dosage of the mutant alleles."( A yeast phosphofructokinase insensitive to the allosteric activator fructose 2,6-bisphosphate. Glycolysis/metabolic regulation/allosteric control.
Boles, E; Heinisch, JJ; Timpel, C, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
D-fructofuranose 2,6-bisphosphateA ketohexose bisphosphate that is D-fructofuranose carrying phosphate groups at positions 2 and 6.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (17)

PathwayProteinsCompounds
Glycolysis6132
Metabolism14961108
Carbohydrate metabolism173120
Glucose metabolism7642
Regulation of glycolysis by fructose 2,6-bisphosphate metabolism56
Fructose and Mannose Degradation1830
Fructosuria1830
Fructose Intolerance, Hereditary1830
Gene expression (Transcription)90249
RNA Polymerase II Transcription72842
Generic Transcription Pathway60839
Transcriptional Regulation by TP5321931
TP53 Regulates Metabolic Genes4324
Fructose and Mannose metabolism ( Fructose and Mannose metabolism )2527
Metabolism overview078
Biochemical pathways: part I0466
Angiopoietin-like protein 8 regulatory pathway15

Research

Studies (660)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990311 (47.12)18.7374
1990's230 (34.85)18.2507
2000's81 (12.27)29.6817
2010's36 (5.45)24.3611
2020's2 (0.30)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 51.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index51.26 (24.57)
Research Supply Index6.51 (2.92)
Research Growth Index4.20 (4.65)
Search Engine Demand Index87.16 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (51.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews37 (5.49%)6.00%
Case Studies4 (0.59%)4.05%
Observational0 (0.00%)0.25%
Other633 (93.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]